PMID- 36445552
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230530
IS  - 1568-5608 (Electronic)
IS  - 0925-4692 (Print)
IS  - 0925-4692 (Linking)
VI  - 31
IP  - 1
DP  - 2023 Feb
TI  - Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
      antibodies in COVID-19 patients: a meta-analysis.
PG  - 275-285
LID - 10.1007/s10787-022-01105-9 [doi]
AB  - OBJECTIVE: This study aims to determine the efficacy and safety of 
      granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 
      patients. METHODS: We searched Cochrane Library, PubMed, Embase, and 
      ClinicalTrials.gov databases until July 27, 2022. Both randomized control trials 
      (RCTs) and cohort studies were included and analyzed separately. The outcomes 
      included mortality, incidence of invasive mechanical ventilation (IMV), 
      ventilation improvement rate (need oxygen therapy to without oxygen therapy), 
      secondary infection, and adverse events (AEs). The odds ratio (OR) with a 95% 
      confidence interval (CI) was calculated by a random-effects meta-analysis model. 
      RESULTS: Five RCTs and 2 cohort studies with 1726 COVID-19 patients were 
      recruited (n = 866 in the GM-CSF antibody group and n = 891 in the control 
      group). GM-CSF antibodies treatment reduced the incidence of IMV, which was 
      supported by two cohort studies (OR 0.16; 95% CI 0.03, 0.74) and three RCTs (OR 
      0.62; 95% CI 0.41, 0.94). GM-CSF antibodies resulted in slight but not 
      significant reductions in mortality (based on two cohort studies and five RCTs) 
      and ventilation improvement (based on one cohort study and two RCTs). The 
      sensitive analysis further showed the results of mortality and ventilation 
      improvement rate became statistically significant when one included study was 
      removed. Besides, GM-CSF antibodies did not increase the risks of the second 
      infection (based on one cohort study and five RCTs) and AEs (based on five RCTs). 
      CONCLUSION: GM-CSF antibody treatments may be an efficacious and well-tolerant 
      way for the treatment of COVID-19. Further clinical evidence is still warranted.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Xi, An-Ran
AU  - Xi AR
AD  - Laboratory of Rheumatology and Institute of TCM Clinical Basic Medicine, College 
      of Basic Medical Science, Zhejiang Chinese Medical University, Binwen Road 548, 
      Hangzhou, 310053, Zhejiang, China.
FAU - Luo, Yi-Jun
AU  - Luo YJ
AD  - Laboratory of Rheumatology and Institute of TCM Clinical Basic Medicine, College 
      of Basic Medical Science, Zhejiang Chinese Medical University, Binwen Road 548, 
      Hangzhou, 310053, Zhejiang, China.
FAU - Guan, Jin-Tao
AU  - Guan JT
AD  - First People's Hospital of Taizhou, Taizhou, 318020, Zhejiang, China.
FAU - Wang, Wei-Jie
AU  - Wang WJ
AD  - The Second Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, 
      310053, Zhejiang, China.
FAU - Xu, Zheng-Hao
AU  - Xu ZH
AUID- ORCID: 0000-0003-0033-525X
AD  - Laboratory of Rheumatology and Institute of TCM Clinical Basic Medicine, College 
      of Basic Medical Science, Zhejiang Chinese Medical University, Binwen Road 548, 
      Hangzhou, 310053, Zhejiang, China. xuzhenghao@zcmu.edu.cn.
AD  - Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang 
      Province, Zhejiang Chinese Medical University, Hangzhou, China. 
      xuzhenghao@zcmu.edu.cn.
LA  - eng
GR  - No. LY22H280007/Natural Science Foundation of Zhejiang/
GR  - 82174005/National Natural Science Foundation of China/
GR  - No. Q2019Y02/Foundation of Zhejiang Chinese Medical University/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20221129
PL  - Switzerland
TA  - Inflammopharmacology
JT  - Inflammopharmacology
JID - 9112626
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Humans
MH  - *Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects
MH  - Granulocyte Colony-Stimulating Factor
MH  - *COVID-19
MH  - Oxygen
PMC - PMC9707187
OTO - NOTNLM
OT  - Antibody
OT  - COVID-19
OT  - Granulocyte-macrophage colony-stimulating factor
OT  - Meta-analysis
COIS- The authors declare that there is no conflict of interest.
EDAT- 2022/11/30 06:00
MHDA- 2023/03/03 06:00
PMCR- 2022/11/29
CRDT- 2022/11/29 11:20
PHST- 2022/09/20 00:00 [received]
PHST- 2022/11/17 00:00 [accepted]
PHST- 2022/11/30 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/11/29 11:20 [entrez]
PHST- 2022/11/29 00:00 [pmc-release]
AID - 10.1007/s10787-022-01105-9 [pii]
AID - 1105 [pii]
AID - 10.1007/s10787-022-01105-9 [doi]
PST - ppublish
SO  - Inflammopharmacology. 2023 Feb;31(1):275-285. doi: 10.1007/s10787-022-01105-9. 
      Epub 2022 Nov 29.